✦ LIBER ✦

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies

✍ Scribed by Lydia Usha; Michael W. Sill; Kathleen M. Darcy; Doris M. Benbrook; Jean A. Hurteau; David P. Michelin; Robert S. Mannel; Parviz Hanjani; Koen De Geest; Andrew K. Godwin

Book ID: 113963133
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 397 KB
Volume: 121
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2011.02.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictive and prognostic angiogenic mar

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

✍ Ernest S. Han; Robert A. Burger; Kathleen M. Darcy; Michael W. Sill; Leslie M. R 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 415 KB

Phase II trial of the mTOR inhibitor, te

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study

✍ Kian Behbakht; Michael W. Sill; Kathleen M. Darcy; Stephen C. Rubin; Robert S. M 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 763 KB